Project Oncology®

Dr. Jennifer Caudle is joined by Dr. Lindsey Roeker, a hematologist and medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss evolving outcome measures and critical diagnostic biomarkers in patients with chronic lymphocytic leukemia.

Dr. Brian T. Hill, a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic, explores some of the most recent—and ongoing—impacts of the COVID-19 pandemic on treatment decision-making for patients with chronic lymphocytic leukemia.

Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.

After viewing the activity, visit the Related tab for supplemental resources.

Non-clear cell renal cell carcinoma is one of the rare diseases with limited treatment data, creating many challenges for oncologists. But could recent updates radically change the landscape? To find out, Dr. Jacob Sands speaks with Dr. Brad McGregor, the Clinical Director for the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, to discuss developments in the management of non-clear cell renal cell carcinoma.

CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the American Society of Clinical Oncology Annual Meeting.

Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.

Dr. Paul Doghramji joins Dr. Wenxin Xu, a physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, to take a look at some of the key factors guiding treatment decisions and disease management for patients with advanced renal cell carcinoma.

Dr. Rana Mckay, a Medical Oncologist and Assistant Professor of Medicine at the University of California San Diego, explores the role of surveillance and frontline local therapy for patients with advanced renal cell carcinoma

ReachMD hosts Drs. Matt Birnholz and Jacob Sands come together to discuss the rationales, limitations, and pathways forward in the treatment of relapsing small cell lung cancer as well as platinum rechallenge therapy.

Dr. David R. Gandara walks us through some of the most recent clinical trial data on non-small cell lung cancer from the 2021 American Society of Clinical Oncology Annual Meeting.